Please select the option that best describes you:
Topics:
Thoracic Malignancies • Medical Oncology
How would you approach adjuvant therapy for patients with mucinous lung adenocarcinoma with an intestinal phenotype?
How would you approach adjuvant therapy for a resected mucinous lung adenocarcinoma (intestinal phenotype) with KRAS G12D, PIK3CA mutations, and PD-L1 0%?